

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

September 1st, 2025

Masaru Okatani appointed Head of Finance and Chief Financial Officer (CFO)

Kanagawa, Japan, September 1st, 2025 – Chordia Therapeutics Inc. (“Chordia”), is pleased to announce the appointment of Masaru Okatani as Head of Finance and Chief Financial Officer (“CFO”). With the appointment of Masaru Okatani, the Company will further strengthen the management team and accelerate the development of innovative anti-cancer therapies.

Profile of Masaru Okatani, CFO

Masaru Okatani	Aug 2007	Joined Ernst & Young ShinNihon LLC
	Aug 2014	Seconded to the Services Trade Division, Economic Affairs Bureau, Ministry of Foreign Affairs of Japan
	Jan 2018	Deloitte Tohmatsu Financial Advisory LLC
	Apr 2022	Executive Member and General Manager of Corporate Management, Sophiamedi Inc.
	Sep 2025	Head of Finance and CFO, Chordia Therapeutics Inc.

Comment from Hiroshi Miyake, CEO

We are delighted to announce the appointment of Masaru Okatani as Head of Finance and CFO of our company. Mr. Okatani holds a Certified Public Accountant qualification and an MBA. Leveraging his extensive background in auditing and M&A advisory firms, he has cultivated a broad and sophisticated knowledge of finance. Most recently, he served as an executive member and General Manager of Corporate Management at Sophiamedi Inc., where he oversaw company-wide back-office operations and demonstrated deep expertise in all aspects of corporate administration. As Head of Finance and CFO, Mr. Okatani will lead the development of a robust financial framework to support our clinical development activities—the key drivers of our growth. We are confident that his leadership will make a significant contribution to our continued success as a publicly listed company.

Comment from Masaru Okatani, CFO

I am deeply honored to be appointed as Head of Finance and CFO of Chordia Therapeutics Inc., a company pioneering the development of the world’s first innovative anti-cancer drug pipeline. Through the continued refinement of our financial strategy and the strategic optimization of our capital policy, I am committed to facilitating the advancement of research and development and driving long-term value creation for all stakeholders. I would like to invite our investors to closely follow

our ongoing journey of challenge and transformation, and I sincerely appreciate your continued support and confidence in our mission.

About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact, IR Kira: ir@chorditherapeutics.com